arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

YD Bio Ltd

YDES

$2.33 ▼ -0.06 (-2.71%) at close

4 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Excellent

Bullish

auto_awesome

Analytical Summary

YD Bio Ltd shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $155.5M

Dividend Yield —

Revenue Growth 16.9% ↘

Op. Margin None

ROIC 184.6% ↗

FCF / Share $-0.12 ↘

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 5, 2026.

4-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$596.82K

↑ +16.9% —

Net Income Profit after all expenses

$-8.31M

↓ -488.8% —

Operating Margin Operating profit as % of sales

-286.5%

↓ -10085.4% —

FCF / Share Free cash flow per share

$-0.12

↓ -500.9% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns ↑

100

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Revenue Growth YoY (%)	16.9% Good Good Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+112%)	45.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+472%)	—	—
EPS Growth YoY (%)	-500.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-488.8% Weak Weak Year-over-year change in net income	N/M	—	—
FCF Growth YoY (%)	-500.9% Weak Weak Year-over-year change in free cash flow	-2219.3% Weak Weak Year-over-year change in free cash flow	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Operating Margin (%) (%)	—	-286.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2010%)	-2.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-119%)	—
Effective Tax Rate (%) (%)	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.8% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	23.2% Fair Fair Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	-276.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2405%)	3.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-68%)	—
FCF Margin (%) (%)	—	-254.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-16.0% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.97x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	-4.13x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Return on Invested Capital (%)	184.6% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-22.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-32.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-38.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-21.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	291.0% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1840%)	-21.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-243%)	59.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+293%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Interest Coverage (x)	—	-1893.69x Weak Weak Operating income divided by interest expense Optimal: > 5x	-4.59x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-6.01M	$-3.13M	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Revenue per Share (USD)	$0.01	$0.01	$0.01	—
Basic EPS, GAAP (USD)	$-0.12	$-0.02	$0.00	—
Free Cash Flow per Share (USD)	$-0.12	$-0.02	$-0.00	—
Book Value per Share (USD)	$-0.04	$0.10	$0.00	—
Tangible Book Value per Share (USD)	$-0.08	$0.06	$0.00	—
Basic Weighted Avg Shares (shares)	66.72M	64.73M	64.73M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Working Capital (USD)	$8.03M	$3.20M	—	—
Total Equity (USD)	$-2.86M	$6.59M	$22.99K	$9.34K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Sales/Revenue/Turnover (USD)	$596.82K	$510.36K	$350.13K	—
Depreciation Expense (USD)	$16.25K	$10.20K	$2.45K	—
Net Income, GAAP (USD)	$-8.31M	$-1.41M	$13.56K	—
Operating Cash Flow (USD)	$-6.60M	$-1.22M	$-55.66K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 4 quarters

YD Bio Ltd

Analytical Summary

4-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare YDES with peers